Cargando…
Bevacizumab versus Ramucirumab in EGFR-Mutated Metastatic Non-Small-Cell Lung Cancer Patients: A Real-World Observational Study
SIMPLE SUMMARY: The addition of bevacizumab or ramucirumab to systemic therapy for EGFR-mutated non-small-cell lung cancer (NSCLC) patients provides survival benefits. No study to date has compared the efficacy and safety of these two antiangiogenic therapies (AATs). This study enrolled patients wit...
Autores principales: | Cheng, Wen-Chien, Shen, Yi-Cheng, Chen, Chieh-Lung, Liao, Wei-Chih, Chen, Chia-Hung, Chen, Hung-Jen, Tu, Chih-Yen, Hsia, Te-Chun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913875/ https://www.ncbi.nlm.nih.gov/pubmed/36765600 http://dx.doi.org/10.3390/cancers15030642 |
Ejemplares similares
-
When to add anti-angiogenesis drugs to EGFR-mutated metastatic non–small cell lung cancer patients: a real-world study from Taiwan
por: Chen, Chieh-Lung, et al.
Publicado: (2022) -
A real-world study comparing perioperative chemotherapy and EGFR-tyrosine kinase inhibitors for treatment of resected stage III EGFR-mutant adenocarcinoma
por: Chen, Chieh-Lung, et al.
Publicado: (2023) -
The Feasibility of Interventional Pulmonology Methods for Detecting the T790M Mutation after the First or Second-Generation EGFR-TKI Resistance of Non-Small Cell Lung Cancer
por: Cheng, Wen-Chien, et al.
Publicado: (2022) -
The Impact of Acquired EGFR T790M Mutation and EGFR Circulating Cell-Free DNA on Survival in Patients with Lung Adenocarcinoma Following EGFR-TKI Therapy
por: Cheng, Wen-Chien, et al.
Publicado: (2021) -
Ischemic stroke in a patient with EGFR‐mutated non–small‐cell lung cancer after treatment with ramucirumab
por: Chen, Guo‐Yu, et al.
Publicado: (2022)